

Resource Summary Report

Generated by [nidm-terms](#) on Jul 28, 2026

BD Biosciences: FACSCanto Flow Cytometer

RRID:SCR_018055

Type: Tool

Proper Citation

BD Biosciences: FACSCanto Flow Cytometer (RRID:SCR_018055)

Resource Information

URL: <https://www.bdbiosciences.com/en-us/instruments/clinical-instruments/clinical-cell-analyzers/facscanto>

Proper Citation: BD Biosciences: FACSCanto Flow Cytometer (RRID:SCR_018055)

Description: Flow cytometry system that performs reliable performance, accuracy, and ease-of-use for clinical diagnostic services. System has 10 color capability, optical enhancements, and 4-3-3 configuration deliver high sensitivity and resolution for accurate results.

Synonyms: Canto-blue and red lasers

Resource Type: instrument resource

Keywords: ABRF, Flow Cytometer, flow cytometry, multicolor analysis, BD FACSCanto, instrument, equipment

Resource Name: BD Biosciences: FACSCanto Flow Cytometer

Resource ID: SCR_018055

Alternate IDs: Model_Number_Canto

Alternate URLs: https://www.bdbiosciences.com/content/dam/bdb/marketing-documents/facscanto_techsspecs.pdf

Record Creation Time: 20220129T080338+0000

Record Last Update: 20260725T190844+0000

Ratings and Alerts

No rating or validation information has been found for BD Biosciences: FACSCanto Flow Cytometer.

No alerts have been found for BD Biosciences: FACSCanto Flow Cytometer.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Carneiro BA, et al. (2025) Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors. Cancer research communications, 5(3), 444.

Juric D, et al. (2025) A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies. Cancer research communications, 5(11), 2025.

Krüger C, et al. (2025) Epidermal growth factor receptor specific immunotherapy for SHH medulloblastoma tested in an in vitro blood-brain barrier-model. Cancer treatment and research communications, 44, 100950.

Maligireddy SS, et al. (2025) Targeting a pathogenic cryptic exon that drives HLRCC to induce exon skipping. Molecular therapy. Nucleic acids, 36(3), 102668.

Fieni C, et al. (2024) Prevention of prostate cancer metastasis by a CRISPR-delivering nanoplatfrom for interleukin-30 genome editing. Molecular therapy : the journal of the American Society of Gene Therapy, 32(11), 3932.

Yada Y, et al. (2024) STIM-mediated calcium influx regulates maintenance and selection of germinal center B cells. The Journal of experimental medicine, 221(1).

Thomas JR, et al. (2024) Abcg2a is the functional homolog of human ABCG2 expressed at the zebrafish blood-brain barrier. Fluids and barriers of the CNS, 21(1), 27.

Boutin L, et al. (2024) Camelid-derived Tcell engagers harnessing human ?? T cells as promising antitumor immunotherapeutic agents. European journal of immunology, 54(8), e2350773.

Robey RW, et al. (2024) The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase Inhibitors. Molecular cancer therapeutics, 23(4), 464.

Chambers C, et al. (2023) SWI/SNF Blockade Disrupts PU.1-Directed Enhancer Programs in Normal Hematopoietic Cells and Acute Myeloid Leukemia. Cancer research, 83(7), 983.

Girone C, et al. (2023) The RIG-I agonist M8 triggers cell death and natural killer cell activation in human papillomavirus-associated cancer and potentiates cisplatin cytotoxicity. *Cancer immunology, immunotherapy : CII*, 72(9), 3097.

Lozano-Rabella M, et al. (2023) Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(12), 2250.

Hurtado-Navarro L, et al. (2023) NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy. *Cell reports. Medicine*, 4(12), 101329.

Fu Y, et al. (2023) A synthetic notch (synNotch) system linking intratumoral immune-cancer cell communication to a synthetic blood biomarker assay. *Frontiers in pharmacology*, 14, 1304194.

Cevallos C, et al. (2022) HIV-induced bystander cell death in astrocytes requires cell-to-cell viral transmission. *Journal of neurochemistry*, 163(4), 338.

Santeford A, et al. (2021) Loss of Mir146b with aging contributes to inflammation and mitochondrial dysfunction in thioglycollate-elicited peritoneal macrophages. *eLife*, 10.

Wang X, et al. (2018) 14-3-3 σ delivered by hepatocellular carcinoma-derived exosomes impaired anti-tumor function of tumor-infiltrating T lymphocytes. *Cell death & disease*, 9(2), 159.